neobookRx
GuidelinesOther guideline

Acute Respiratory Distress Syndrome

Overview Definition and Pathophysiology Clinical Presentation Differential Diagnosis Diagnostic Tests Management Medications Complications Patient Education References and Guidelines Notes for HCPs Clinical Highlights Recommended Reads Field Triage Clinical Setting Condition Type Pulmonology Emergency ICU Acute Overview Condition Name: Acute Respiratory Distress Syndrome (ARDS) ICD-10 Code = J80

Overview

Definition and Pathophysiology

Clinical Presentation

Differential Diagnosis

Diagnostic Tests

Management

Medications

Complications

Patient Education

References and Guidelines

Notes for HCPs

Clinical Highlights

Recommended Reads

Field

 Triage Clinical Setting Condition Type
Pulmonology Emergency ICU Acute

Overview

Condition

  • Name: Acute Respiratory Distress Syndrome (ARDS)
  • ICD-10 Code = J80

Epidemiology

Prevalence

  • In South Africa, data on ARDS prevalence are limited but reflect international trends
  • Global incidence ranges from 64.2 to 78.9 cases per 100,000 person-years
  • Up to 23% of mechanically ventilated patients meet ARDS criteria

Severity Distribution

  • Approximately 25% of ARDS cases are mild, with the remaining 75% classified as moderate or severe
  • Mild cases have a significant risk of progression to moderate or severe ARDS

Mortality Rates

  • Mortality rates are commensurate with disease severity: 27% for mild, 32% for moderate, and 45% for severe ARDS
  • Overall pooled mortality rate stands at 43%

Risk Factors

  • Advanced age
  • Female gender
  • Smoking
  • Alcohol use
  • Underlying conditions like sepsis, trauma, and pancreatitis

Risk Factors

Pulmonary Insults

  • Aspiration of gastric contents
  • Diffuse pneumonia (e.g., SARS, COVID-19)
  • Toxic gas inhalation (e.g., nitrogen dioxide, chlorine)
  • Lung contusion
  • High-altitude exposure

Systemic Insults

  • Sepsis
  • Pancreatitis
  • Multiple transfusions
  • Non-thoracic trauma
  • Drug overdose (e.g., opioids, aspirin)
  • Cardiopulmonary bypass
  • Shock
  • Disseminated intravascular coagulation

Impact on Quality of Life

Functional Impairment

  • Profound dyspnoea and hypoxaemia
  • Increased healthcare utilisation due to prolonged mechanical ventilation and ICU stays
  • High rates of subsequent multiple organ failure

Long-term Outcomes

  • Significant weight loss and muscle weakness
  • Cognitive changes persisting months after discharge
  • Many survivors report reduced exercise tolerance and dyspnoea on exertion

Regional and Socioeconomic Variations

Urban vs. Rural

  • Higher incidence in urban areas potentially due to increased pollution and stressors

Socioeconomic Factors

  • Lower-income individuals may face higher risks due to limited access to timely and adequate healthcare

Clinical Impact and Considerations

Healthcare Utilisation

  • High demand on ICU resources and specialised care teams
  • Prolonged hospital stays and need for rehabilitation services post-discharge

Economic Burden

  • Increased costs due to extended ICU stays, mechanical ventilation, and associated treatments
  • Financial strain on healthcare systems, particularly in resource-limited settings

Definition and Pathophysiology

Definition

Acute Respiratory Distress Syndrome (ARDS)

  • A severe, life-threatening condition characterised by acute onset of hypoxaemia and bilateral pulmonary infiltrates in the absence of left atrial hypertension
  • Diagnosed based on clinical criteria, including acute onset, bilateral infiltrates on chest imaging, and a PaO2/FiO2 ratio of less than 300 mm Hg with a positive end-expiratory pressure (PEEP) of at least 5 cm H2O, as per the Berlin definition

Pathophysiology

Initial Injury and Inflammation

  • ARDS begins with an inciting event such as sepsis, pneumonia, trauma, or aspiration that triggers a systemic inflammatory response
  • Inflammatory mediators like cytokines are released, leading to the activation of neutrophils and other immune cells

Alveolar-Capillary Barrier Damage

  • The inflammatory response results in damage to the capillary endothelium and alveolar epithelium
  • Increased vascular permeability allows fluid, proteins, and cellular debris to leak into the alveoli, causing pulmonary oedema

Impaired Gas Exchange

  • Alveolar flooding and collapse (atelectasis) reduce the surface area available for gas exchange, leading to severe hypoxaemia
  • The formation of hyaline membranes and microthrombi further impairs gas exchange and lung compliance

Phases of ARDS

  • Exudative phase:
    - Occurs within the first 7 days of the initial insult
    - Characterised by diffuse alveolar damage, oedema, and hyaline membrane formation
  • Proliferative phase:
    - Begins 7 to 14 days after the onset of ARDS
    - Involves the proliferation of type II alveolar cells, fibroblasts, and myofibroblasts, leading to alveolar repair and organisation
  • Fibrotic phase:
    - May develop if ARDS persists beyond 14 days
    - Marked by extensive fibrosis and collagen deposition, which can lead to chronic lung disease and prolonged ventilator dependence

Ventilation-Perfusion Mismatch

  • The heterogeneous nature of lung injury in ARDS results in areas of the lung that are poorly ventilated but well perfused, contributing to a ventilation-perfusion (V/Q) mismatch
  • This mismatch exacerbates hypoxaemia and complicates oxygenation strategies

Pulmonary Hypertension

  • Inflammatory mediators and hypoxic vasoconstriction can lead to increased pulmonary vascular resistance and pulmonary hypertension
  • Pulmonary hypertension increases the workload on the right ventricle, potentially leading to right ventricular dysfunction

Histopathological Findings

  • Early stages show diffuse alveolar damage with neutrophilic infiltration, alveolar oedema, and formation of hyaline membranes
  • Later stages may show interstitial fibrosis, fibroblast proliferation, and collagen deposition

Clinical Presentation

Symptoms

Dyspnoea

  • Rapid onset of severe shortness of breath
  • Usually occurs within 6 to 72 hours of the inciting event

Hypoxaemia

  • Persistent low blood oxygen levels despite supplemental oxygen therapy
  • Often requires mechanical ventilation

Tachypnoea

  • Rapid, shallow breathing
  • Respiratory rate typically above 30 breaths per minute

Fatigue and Weakness

  • Profound exhaustion and lack of energy
  • May be exacerbated by the underlying cause of ARDS (e.g., sepsis, trauma)

Chest Discomfort

  • Reports of chest tightness or pain due to severe lung involvement
  • Not a predominant symptom but may be present

Confusion and Altered Mental Status

  • Due to hypoxaemia, patients may experience confusion, agitation, or a decreased level of consciousness

Signs

Respiratory Distress

  • Laboured breathing with use of accessory muscles
  • Intercostal and suprasternal retractions noted on physical examination

Cyanosis

  • Bluish discolouration of the lips, fingertips, and skin due to inadequate oxygenation

Auscultation

  • Bilateral crackles (rales) heard throughout lung fields
  • Often more pronounced in the lower lobes

Tachycardia

  • Increased heart rate as a physiological response to hypoxaemia
  • Heart rate often exceeds 100 beats per minute

Fever

  • Elevated body temperature, particularly if ARDS is secondary to an infectious cause such as pneumonia or sepsis

Diagnostic Criteria

Berlin Definition

  • Timing:
    - Acute onset within one week of a known clinical insult or new/worsening respiratory symptoms
  • Imaging:
    - Bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules on chest radiograph or CT scan
  • Origin of oedema:
    - Respiratory failure not fully explained by cardiac failure or fluid overload; objective assessment (e.g., echocardiography) to exclude hydrostatic oedema if no risk factor is present
  • Oxygenation:
    - Severity of hypoxaemia defined by the PaO2/FiO2 ratio with PEEP ≥ 5 cm H2O
    - Mild: 200 mm Hg < PaO2/FiO2 ≤ 300 mm Hg
    - Moderate: 100 mm Hg < PaO2/FiO2 ≤ 200 mm Hg
    - Severe: PaO2/FiO2 ≤ 100 mm Hg

Additional Diagnostic Considerations

Comorbid Conditions

  • Assessment for underlying or contributing conditions such as sepsis, pancreatitis, or trauma
  • Evaluation for other pulmonary diseases that may mimic ARDS, such as cardiogenic pulmonary oedema or diffuse alveolar haemorrhage

Medical Evaluation

  • Comprehensive history and physical examination to identify the triggering event
  • Routine blood tests including complete blood count, renal and liver function tests, and coagulation profile
  • Arterial blood gas analysis to assess the degree of hypoxaemia and acid-base status

Imaging Studies

  • Chest radiography to identify bilateral infiltrates
  • CT scan of the chest for a more detailed evaluation of lung pathology and to rule out alternative diagnoses

Functional Impact

Quality of Life

  • Significant impairment due to prolonged hospitalisation and need for intensive care
  • Post-ARDS survivors often face long-term physical, psychological, and cognitive challenges

Patient-Reported Outcomes

  • Use of validated scales such as the Sequential Organ Failure Assessment (SOFA) score to track disease severity and prognosis
  • Patient diaries to document symptoms, response to treatment, and identify potential triggers for exacerbations

Differential Diagnosis

Conditions to Consider

Cardiogenic Pulmonary Oedema

  • Often presents with similar symptoms to ARDS but due to left ventricular heart failure
  • Characterised by bilateral pulmonary infiltrates on chest X-ray, elevated pulmonary capillary wedge pressure, and signs of fluid overload

Acute Interstitial Pneumonia (AIP)

  • Idiopathic condition similar to ARDS in its acute presentation
  • Rapid onset of respiratory failure with diffuse alveolar damage on histology, but no identifiable cause

Diffuse Alveolar Haemorrhage (DAH)

  • Presents with haemoptysis, anaemia, and bilateral infiltrates on chest imaging
  • Associated with autoimmune diseases like Goodpasture syndrome or systemic lupus erythematosus

Exacerbation of Chronic Interstitial Lung Disease

  • Patients with underlying interstitial lung disease may experience acute worsening mimicking ARDS
  • Typically presents with pre-existing pulmonary fibrosis on imaging and a history of chronic lung disease

Bilateral Pneumonia

  • Infection causing bilateral lung infiltrates and respiratory distress
  • Confirmed by microbiological evidence and response to antibiotics

Pulmonary Vasculitis

  • Presents with haemoptysis, renal involvement, and systemic symptoms
  • Diagnosed through serological markers and often confirmed by lung biopsy

Acute Eosinophilic Pneumonia

  • Characterised by acute onset of respiratory symptoms, hypoxaemia, and pulmonary infiltrates with eosinophilia in bronchoalveolar lavage fluid
  • Often triggered by new medications or environmental exposures

Organising Pneumonia

  • Presents with subacute onset of cough, dyspnoea, and bilateral infiltrates
  • Histological pattern of organising pneumonia seen on lung biopsy, often responds to corticosteroids

Cryptogenic Organising Pneumonia (COP)

  • Idiopathic form of organising pneumonia with similar presentation and treatment response
  • Often presents with flu-like symptoms and migratory pulmonary infiltrates

Disseminated Malignancy

  • Metastatic cancer can present with respiratory distress and diffuse pulmonary infiltrates
  • Diagnosis confirmed through imaging, biopsy, and identification of primary malignancy

Key Differentiators

Cardiogenic Pulmonary Oedema

  • Presence of elevated jugular venous pressure, peripheral oedema, and response to diuretics
  • Echocardiography shows reduced left ventricular function

Acute Interstitial Pneumonia (AIP)

  • No identifiable cause, rapid progression, and often poorer prognosis compared to ARDS
  • Lung biopsy shows diffuse alveolar damage without an inciting event

Diffuse Alveolar Haemorrhage (DAH)

  • Presence of haemoptysis, anaemia, and evidence of haemorrhage in bronchoalveolar lavage fluid
  • Often associated with autoimmune markers

Exacerbation of Chronic Interstitial Lung Disease

  • History of chronic lung disease with baseline imaging showing interstitial fibrosis
  • Acute exacerbation often triggered by infection or other insults

Bilateral Pneumonia

  • Fever, productive cough, and leukocytosis on complete blood count
  • Microbiological confirmation through sputum culture or blood cultures

Pulmonary Vasculitis

  • Systemic symptoms like fever, weight loss, and arthralgia
  • Positive serological markers such as ANCA or anti-GBM antibodies

Acute Eosinophilic Pneumonia

  • Peripheral eosinophilia and eosinophils in bronchoalveolar lavage fluid
  • Rapid improvement with corticosteroids

Organising Pneumonia

  • Subacute presentation, migratory infiltrates, and good response to corticosteroids
  • Histology shows intra-alveolar granulation tissue and fibrosis

Cryptogenic Organising Pneumonia (COP)

  • Similar to organising pneumonia but idiopathic
  • Presents with systemic symptoms and migratory infiltrates

Disseminated Malignancy

  • Evidence of primary tumour elsewhere, weight loss, and systemic symptoms
  • Imaging and biopsy confirm metastatic disease

Diagnostic Tests

Initial Tests

Clinical Evaluation

  • History and physical examination:
    - Detailed patient history including the onset, duration, and severity of symptoms
    - Assessment of potential triggering events such as trauma, infection, or aspiration
    - Comprehensive physical examination focusing on signs of respiratory distress, cyanosis, and systemic involvement

Blood Tests

  • Arterial blood gas (ABG) analysis:
    - Essential for assessing the degree of hypoxaemia and acid-base balance
    - Provides crucial information on PaO2, PaCO2, and pH levels
  • Full blood count (CBC):
    - Identifies leukocytosis indicative of infection or inflammation
    - Assesses for anaemia which can exacerbate hypoxaemia
  • Renal and liver function tests:
    - Monitors organ function, especially in patients at risk of multi-organ failure
  • Electrolyte panel:
    - Detects imbalances that can affect respiratory and cardiac function
  • Coagulation profile:
    - Important for identifying coagulopathies which are common in critically ill patients

Imaging Studies

  • Chest radiography:
    - Initial imaging modality to identify bilateral pulmonary infiltrates
    - Helps to rule out other causes of respiratory distress such as pleural effusions or pneumothorax
  • Computed tomography (CT) Scan:
    - Provides a detailed view of lung parenchyma
    - Useful for differentiating ARDS from other conditions like pulmonary embolism or interstitial lung disease

ECG and Cardiac Evaluation

  • Electrocardiogram (ECG):
    - Essential for ruling out cardiac causes of respiratory distress
    - Identifies arrhythmias or signs of myocardial ischemia that can coexist with ARDS
  • Echocardiography:
    - Assesses left ventricular function and excludes cardiogenic pulmonary oedema
    - Non-invasive method to evaluate pulmonary artery pressures

Advanced Tests

Bronchoscopy

  • Bronchoalveolar lavage (BAL):
    - Used to identify infectious agents in the lower respiratory tract
    - Helps in diagnosing conditions like diffuse alveolar haemorrhage or eosinophilic pneumonia

Pulmonary Function Tests

  • Spirometry:
    - Not typically performed during acute ARDS but valuable in follow-up to assess long-term lung function

Invasive Monitoring

  • Pulmonary artery catheterisation:
    - Used selectively to measure pulmonary capillary wedge pressure (PCWP) and differentiate ARDS from cardiogenic pulmonary oedema
    - Controversial due to potential complications and limited evidence of benefit

Non-Invasive Monitoring

  • Thoracic ultrasound:
    - Useful for assessing pleural effusions, lung consolidation, and guiding fluid management
    - Non-invasive and can be performed at the bedside

Additional Diagnostic Considerations

Microbiological Testing

  • Blood and sputum cultures:
    - Identifies causative organisms in cases of suspected infectious aetiology
    - Guides appropriate antibiotic therapy

Biomarker Analysis

  • Procalcitonin and C-reactive protein (CRP):
    - Elevated levels indicate bacterial infection and systemic inflammation
    - Helps in distinguishing between infectious and non-infectious causes of ARDS

Clinical Pitfalls

  • Regular reassessment:
    - Continuous monitoring and repeated evaluations are crucial due to the dynamic nature of ARDS
  • Multidisciplinary approach:
    - Collaboration with critical care specialists, pulmonologists, infectious disease experts, and other relevant healthcare providers ensures comprehensive care
  • Holistic view:
    - Consider the overall clinical picture, including patient history, physical examination, and diagnostic tests to guide treatment decisions effectively

Management

First-line Therapy

Supportive Care

Oxygen Therapy

  • Administer supplemental oxygen to maintain PaO2 > 55 mm Hg or SaO2 > 88%
  • Use high-flow nasal cannula (HFNC) or non-rebreather mask initially

Mechanical Ventilation

  • Initiate in cases of refractory hypoxaemia despite oxygen therapy
  • Employ lung-protective strategies with low tidal volumes (4-8 mL/kg ideal body weight) and PEEP ≥ 5 cm H2O
  • Aim for plateau pressures < 30 cm H2O to prevent ventilator-induced lung injury

Prone Positioning

  • Consider early prone positioning for 12-16 hours per day in moderate to severe ARDS
  • Shown to improve oxygenation and reduce mortality

Pharmacological Therapy

Neuromuscular Blockade

  • Cisatracurium infusion for up to 48 hours in severe ARDS to facilitate mechanical ventilation and reduce lung injury

Steroids

  • Consider corticosteroids (e.g., methylprednisolone) in selected cases, particularly early in the disease course or with a PaO2/FiO2 ratio < 200

Vasoactive Agents

  • Use vasopressors (e.g., norepinephrine) to maintain mean arterial pressure > 65 mm Hg in patients with septic shock or hypotension

Sedation and Analgesia

  • Ensure adequate sedation and pain control, typically with agents like midazolam, propofol, or fentanyl

Non-Pharmacological Therapy

Fluid Management

  • Conservative fluid management strategy once shock is resolved to prevent fluid overload
  • Balance between avoiding hypoperfusion and reducing pulmonary oedema

Nutrition

  • Early enteral nutrition is preferred to support metabolic needs
  • Use high-protein, low-carbohydrate formulas to minimise CO2 production

ECMO (Extracorporeal Membrane Oxygenation)

  • Consider for refractory hypoxaemia despite maximal conventional therapy
  • Typically used as a bridge to recovery or lung transplantation

Second-line Treatment

Advanced Ventilatory Strategies

High-Frequency Oscillatory Ventilation (HFOV)

  • May be considered in specialised centres for severe ARDS not responding to conventional ventilation

Airway Pressure Release Ventilation (APRV)

  • Alternate mode of ventilation that can be considered in refractory cases

Adjunctive Therapies

Inhaled Vasodilators

  • Inhaled nitric oxide or prostacyclin for selective pulmonary vasodilation and improved oxygenation

Recruitment Manoeuvres

  • Periodic application of increased airway pressure to open collapsed alveoli, used with caution

Referral

Indications for Specialist Referral

Intensivist/Pulmonologist

  • For management of severe ARDS and complex ventilation strategies
  • When considering ECMO or other advanced therapies

Infectious Disease Specialist

  • For patients with sepsis or suspected infectious aetiology

Nutritionist/Dietitian

  • To optimise enteral nutrition and caloric intake

Physiotherapist

  • For mobilisation and rehabilitation during the recovery phase

Monitoring

Regular Follow-up

Daily Assessments

  • Regular clinical evaluations to monitor respiratory status and response to therapy
  • Serial ABGs to guide oxygen and ventilation management

Laboratory Tests

  • Regular monitoring of blood counts, electrolytes, renal, and liver function
  • Check inflammatory markers to assess ongoing infection or inflammation

Long-term Management

Weaning from Mechanical Ventilation

  • Gradual reduction in ventilatory support as the patient improves
  • Use weaning protocols and trials to assess readiness for extubation

Rehabilitation

  • Early mobilisation and physiotherapy to prevent deconditioning and muscle wasting
  • Psychological support to address anxiety, PTSD, or depression post-ARDS

Follow-up

Routine Follow-ups

Outpatient Monitoring

  • Schedule follow-up appointments to monitor lung function and overall recovery
  • Use pulmonary function tests to assess long-term impact on respiratory function

Patient and Family Involvement

  • Educate patients and families about the disease course and recovery expectations
  • Provide resources for support groups and rehabilitation services

Patient Education

Medication Adherence

Importance of Following Prescribed Regimen

  • Ensure understanding of medication schedules and potential side effects
  • Educate on the importance of adherence to improve outcomes

Lifestyle and Self-care

Healthy Lifestyle Choices:

  • Encourage smoking cessation and avoidance of respiratory irritants
  • Promote a balanced diet and regular exercise to support recovery

Medications

Drug Name

Neuromuscular Blockers

  • Cisatracurium
    - Used for deep sedation in severe ARDS to facilitate mechanical ventilation

Corticosteroids

  • Methylprednisolone
    - Administered in moderate to severe ARDS to reduce inflammation

Vasoactive Agents

  • Norepinephrine
    - Used to maintain mean arterial pressure in patients with septic shock

Sedatives and Analgesics

  • Midazolam
    - For sedation in mechanically ventilated patients
  • Propofol
    ​​- Used for sedation with rapid onset and short duration​​​​​- 
  • Fentanyl
    - Preferred for analgesia due to its potency and short half-life

Antibiotics

  • Broad-spectrum antibiotics
    - Empirical treatment for suspected or confirmed bacterial infections

Anticoagulants

  • Low molecular weight heparin (LMWH)
    - Used for deep vein thrombosis (DVT) prophylaxis

Posology (Dosage)

Drug Dosage & Frequency Clinical Notes
Neuromuscular Blockers
Cisatracurium Initial bolus: 0.1-0.2 mg/kg IV.
Continuous infusion: 0.1-0.2 mg/kg/hour.

 

Adjusted based on clinical response.
Corticosteroids
Methylprednisolone Initial dose: 1 mg/kg/day IV. Tapered over 7-14 days based on clinical response and improvement.
Vasoactive Agents
Norepinephrine Initial dose: 0.01-0.1 µg/kg/min IV infusion. Titrate to maintain mean arterial pressure ≥ 65 mm Hg.
Sedatives and Analgesics
Midazolam Initial dose: 0.01-0.05 mg/kg IV bolus.
Continuous infusion: 0.02-0.1 mg/kg/hour.

 

Titrated to desired sedation level.
Propofol Initial dose: 5 µg/kg/min IV infusion.
Maintenance dose: 5-50 µg/kg/min.

 

Adjusted as needed.
Fentanyl Initial dose: 1-2 µg/kg IV bolus.
Continuous infusion: 1-2 µg/kg/hour.

 

Titrated to pain relief.
Antibiotics
Broad-spectrum antibiotics Dosage varies based on the specific antibiotic used and patient’s renal function. Common choices include piperacillin-tazobactam, meropenem, and vancomycin.
Anticoagulants
Low molecular weight heparin (LMWH) Enoxaparin: 40 mg subcutaneously daily for DVT prophylaxis. Adjust dose based on renal function.

Side Effects

Neuromuscular Blockers

Cisatracurium

  • Muscle weakness
  • Prolonged paralysis if not monitored correctly

Corticosteroids

Methylprednisolone

  • Hyperglycaemia
  • Increased risk of infection
  • Muscle wasting and osteoporosis with prolonged use

Vasoactive Agents

Norepinephrine

  • Arrhythmias
  • Peripheral ischaemia

Sedatives and Analgesics

Midazolam

  • Respiratory depression
  • Hypotension

Propofol

  • Hypotension
  • Hypertriglyceridaemia

Fentanyl

  • Respiratory depression
  • Constipation

Antibiotics

Broad-spectrum antibiotics

  • Antibiotic-associated diarrhoea
  • Clostridioides difficile infection
  • Nephrotoxicity with certain agents

Anticoagulants

Low molecular weight heparin (LMWH)

  • Bleeding
  • Heparin-induced thrombocytopenia (HIT)

Interactions

Neuromuscular Blockers

Cisatracurium

  • Enhanced effects with other muscle relaxants
  • Reduced effect with chronic use of anticonvulsants

Corticosteroids

Methylprednisolone

  • May increase blood glucose levels, requiring adjustment in diabetic medications
  • Interaction with NSAIDs increases the risk of gastrointestinal bleeding

Vasoactive Agents

Norepinephrine

  • Reduced efficacy with β-blockers
  • Increased risk of arrhythmias with concurrent use of digoxin

Sedatives and Analgesics

Midazolam

  • Enhanced sedation with concurrent use of other CNS depressants
  • Grapefruit juice can increase midazolam levels

Propofol

  • Potentiation of sedative effects with other CNS depressants

Fentanyl

  • Increased risk of respiratory depression with other opioids or sedatives

Antibiotics

Broad-spectrum antibiotics

  • Potential for drug interactions varies with specific antibiotics
  • Monitor for nephrotoxicity when combined with other nephrotoxic drugs

Anticoagulants

Low molecular weight heparin (LMWH)

  • Increased risk of bleeding with concurrent use of antiplatelets or NSAIDs
  • Monitor INR closely if used with warfarin

Complications

Acute Complications

Barotrauma

  • Risk of barotrauma:
    - High PEEP and mechanical ventilation pressures can lead to pneumothorax, pneumomediastinum, and subcutaneous emphysema
  • Management:
    - Regular monitoring with chest radiographs and adjustment of ventilatory settings as needed

Nosocomial Infections

  • Ventilator-associated pneumonia (VAP):
    - Prolonged mechanical ventilation increases the risk of VAP
  • Line sepsis:
    - Central venous catheters can become sources of bloodstream infections
  • Management:
    - Strict aseptic techniques, regular monitoring, and early antibiotic therapy when infection is suspected

Multiorgan Failure

  • Progression to multiorgan dysfunction syndrome (MODS):
    - Due to severe hypoxaemia and systemic inflammation, patients may develop renal, hepatic, and cardiovascular failure
  • Management:
    - Supportive care for affected organs and prevention of further organ injury

Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)

  • Increased risk:
    - Immobility and critical illness predispose patients to thromboembolic events
  • Management:
    - Prophylactic anticoagulation with low molecular weight heparin (LMWH) and mechanical prophylaxis with compression devices

Psychological Distress

  • Acute stress reaction:
    - Patients and families may experience significant psychological stress due to the severity of ARDS
  • Management:
    - Psychological support and counselling for patients and their families

Chronic Complications

Prolonged Mechanical Ventilation

  • Dependence on ventilation:
    - Difficulty weaning off mechanical ventilation, leading to prolonged ICU stay
  • Management:
    - Gradual weaning protocols and specialised rehabilitation support

Fibrosis and Chronic Lung Disease

  • Long-term lung damage:
    - Fibrotic changes in the lungs can result in chronic respiratory insufficiency
  • Management:
    - Pulmonary rehabilitation and long-term oxygen therapy as needed

Neurocognitive Impairment

  • Cognitive dysfunction:
    - Survivors of ARDS may experience memory loss, difficulty concentrating, and other cognitive deficits
  • Management:
    - Cognitive rehabilitation and support services to aid recovery

Post-traumatic Stress Disorder (PTSD)

  • Psychological impact:
    - ICU survivors are at risk of developing PTSD due to the traumatic experience of severe illness and intensive care
  • Management:
    - Psychological interventions and regular mental health follow-up

Muscle Weakness and Functional Impairment

  • Critical illness polyneuropathy and myopathy:
    - Prolonged immobilisation and systemic inflammation can lead to significant muscle weakness
  • Management:
    - Early mobilisation, physiotherapy, and nutritional support

Gastrointestinal Complications

  • Stress ulcers and GI bleeding:
    - Increased risk due to critical illness and use of steroids
  • Management:
    - Prophylactic use of proton pump inhibitors (PPIs) or H2 blockers

Preventive Measures

Prophylactic Interventions

  • Regular monitoring:
    - Continuous monitoring for early signs of complications and prompt intervention
  • Early mobilisation:
    - Implement early physical therapy to prevent muscle atrophy and functional decline

Patient Education

  • Treatment adherence:
    - Educate patients and families on the importance of adhering to treatment plans
  • Recognising complications:
    - Training on recognising early signs of complications and seeking timely medical help

Lifestyle Modifications

  • Healthy lifestyle:
    - Encourage a balanced diet, regular physical activity, and smoking cessation
  • Stress management:
    - Promote techniques such as mindfulness, relaxation exercises, and support groups

Regular Follow-up

  • Scheduled appointments:
    - Regular follow-up appointments to monitor progress and adjust treatment as needed
  • Use of validated tools:
    - Employ tools like pulmonary function tests and mental health assessments to track recovery

Impact on Quality of Life

Daily Functioning

  • Impairment:
    - ARDS can significantly impair daily activities and reduce the quality of life
  • Support systems:
    - Effective treatment and robust support systems are essential to improving functionality and well-being

Increased Healthcare Utilisation

  • Frequent interventions:
    - High demand for medical and psychological interventions post-recovery
  • Comprehensive care plans:
    - Minimise acute episodes and improve long-term management through comprehensive care plans

Economic Burden

  • Cost of treatment:
    - Direct costs from prolonged ICU stays and indirect costs from loss of productivity
  • Economic support:
    - Addressing financial factors is crucial for long-term management and adherence to treatment

Psychological Effects

  • Chronic stress:
    - Ongoing stress and anxiety can impact mental health
  • Integrated care:
    - Address both physical and mental health aspects through integrated care

Patient Education

Lifestyle Modifications

Sleep Hygiene

  • Consistent sleep schedule:
    - Establish a regular sleep routine by going to bed and waking up at the same time every day
  • Sleep environment:
    - Create a quiet, dark, and comfortable sleep environment
    - Avoid screens and stimulants such as caffeine close to bedtime

Physical Activity

  • Regular exercise:
    - Engage in at least 30 minutes of moderate exercise most days of the week
    - Activities like walking, yoga, and swimming can improve overall health and reduce stress

Healthy Diet

  • Balanced nutrition:
    - Maintain a diet rich in fruits, vegetables, whole grains, and lean proteins
    - Limit intake of sugar, caffeine, and processed foods, which can negatively affect energy levels and recovery

Preventive Measures

Stress Management

  • Relaxation techniques:
    - Practise deep breathing, meditation, or progressive muscle relaxation
  • Stress identification:
    - Identify sources of stress and manage them through planning and support

Routine and Structure

  • Daily routine:
    - Establish a structured daily routine to provide predictability and balance
    - Allocate time for work, rest, and leisure activities to manage daily demands effectively

Social Support

  • Stay connected:
    - Maintain connections with family and friends for emotional support
    - Consider joining support groups for individuals with similar health conditions to share experiences and coping strategies

Support Resources

Patient Support Groups

  • Participation:
    - Join local or online support groups for individuals recovering from ARDS
    - Support groups provide emotional support and practical advice

Educational Materials

  • Access information:
    - Utilise reliable sources for information on ARDS, its symptoms, and management
    - Educational brochures, websites, and mobile apps can offer guidance and support

Counselling and Therapy

  • Regular sessions:
    - Engage in regular counselling or therapy sessions to manage stress and anxiety
    - Cognitive behavioural therapy (CBT) and other therapeutic approaches can be beneficial

Medication Adherence

Importance of Medication

  • Education:
    - Emphasise the importance of taking medications as prescribed
    - Discuss potential side effects and management strategies, and caution against abrupt discontinuation

Medication Diary

  • Tracking:
    - Encourage keeping a medication diary to track dosages and effects
    - Use reminders and pill organisers to ensure consistent medication intake

Symptom Tracking

Symptom Diary

  • Documentation:
    - Keep a diary of symptoms, mood changes, and triggers
    - Symptom tracking helps in adjusting treatment plans and identifying patterns

Communication with Healthcare Providers

Regular Check-ins

  • Open communication:
    - Maintain open communication with the healthcare team
    - Regular check-ins help monitor symptom progression and the effectiveness of treatments

Reporting Symptoms

  • Prompt reporting:
    - Report any new or worsening symptoms promptly
    - Discuss side effects of medications to adjust treatment if necessary

Holistic Approaches

Complementary Therapies

  • Exploration:
    - Consider complementary therapies such as acupuncture or mindfulness
    - Discuss these therapies with healthcare providers to avoid interactions and ensure they complement conventional treatments

Long-Term Management

Ongoing Care

  • Expectation management:
    - Understand that managing ARDS may require ongoing care
    - Set realistic expectations about symptom control and the potential need for long-term lifestyle adjustments

Active Role in Care

  • Patient empowerment:
    - Encourage taking an active role in care and decision-making processes
    - Provide tools and resources to empower patients in managing their condition

References and Guidelines

Key References

  • Abbas R, El Ali M, Fitzpatrick ME, Rivera-Lebron B. Acute Respiratory Distress Syndrome. In: Papadakis MA, McPhee SJ, Rabow MW, editors. Current Medical Diagnosis & Treatment 2024. New York: McGraw-Hill; 2024

Clinical Guidelines

  • Surviving Sepsis Campaign. International Guidelines for the Management of Sepsis and Septic Shock 2024:
    - Provides detailed recommendations for the management of sepsis and septic shock, which are common causes of ARDS. Includes guidance on fluid resuscitation, vasopressor use, and adjunctive therapies
  • American Thoracic Society (ATS). Clinical Practice Guideline: Mechanical Ventilation in Adult Patients with Acute Respiratory Distress Syndrome:
    - Offers evidence-based recommendations on the use of mechanical ventilation in ARDS, focusing on lung-protective strategies, PEEP settings, and use of adjunctive measures like ECMO
  • World Health Organization (WHO). Clinical Management of Severe Acute Respiratory Infection (SARI) when COVID-19 Disease is Suspected:
    - Guidelines on the management of severe acute respiratory infections, including ARDS, in the context of the COVID-19 pandemic. Highlights infection control measures, supportive care, and therapeutic options
  • South African Thoracic Society (SATS). Guidelines for the Management of Acute Respiratory Distress Syndrome:
    - Specific recommendations tailored to the South African context, focusing on resource-sensitive approaches to the diagnosis and management of ARDS. Includes guidelines for the use of mechanical ventilation, corticosteroids, and supportive care

Notes for HCPs

Clinical Pearls and Pitfalls

Ensure Patient Compliance with Treatment

Education on Treatment Adherence

  • Educate patients and families on the importance of adhering to prescribed medications and treatments
  • Provide clear instructions on the proper use of medications, including potential side effects and the importance of not abruptly discontinuing treatments

Monitor for Drug Interactions

Regular Medication Reviews

  • Regularly review patient medication lists to identify potential drug interactions, particularly with sedatives, neuromuscular blockers, and corticosteroids
  • Be cautious with polypharmacy, especially in critically ill patients with multiple comorbid conditions

Recognise and Manage Comorbid Conditions

Comprehensive Assessment

  • Screen for and address comorbid conditions such as sepsis, cardiac dysfunction, and renal impairment
  • Consider the impact of these conditions on ARDS management and tailor treatment plans accordingly

Evaluate and Address Lifestyle Factors

Encourage Healthy Habits

  • Promote regular physical activity and a balanced diet to support overall health and recovery
  • Emphasise the importance of sleep hygiene and stress management techniques

Be Vigilant for Acute Symptoms and Complications

Prompt Management of Acute Complications

  • Address symptoms such as severe hypoxaemia, barotrauma, and multiorgan failure promptly
  • Monitor for nosocomial infections, particularly ventilator-associated pneumonia, and initiate appropriate interventions early

Customise Treatment Plans

Individualised Care

  • Tailor pharmacological treatments based on individual patient factors, including age, comorbid conditions, and previous response to treatments
  • Adjust dosages carefully and monitor for therapeutic effectiveness and adverse effects

Educate Patients About Prevention

Preventive Measures

  • Discuss the importance of lifestyle modifications and adherence to treatment plans to prevent complications
  • Educate patients on recognising early signs of deterioration and seeking timely medical intervention

Consider the Use of Non-Pharmacological Interventions

Supportive Therapies

  • Suggest complementary therapies such as physical therapy and rehabilitation programmes
  • Encourage participation in support groups and educational programmes to enhance coping strategies

Screen for and Manage Psychological Comorbidities

Psychological Support

  • Recognise that ARDS can significantly impact mental health, leading to anxiety, depression, and PTSD
  • Consider referrals to mental health professionals for comprehensive psychological care

Set Realistic Expectations

Long-Term Management

  • Educate patients and families that managing ARDS and its sequelae often requires a long-term commitment to treatment and lifestyle adjustments
  • Emphasise the importance of ongoing follow-ups and preventive measures to maintain stability and prevent relapse

Follow-up and Monitoring

Regular Follow-Ups

  • Schedule regular follow-up appointments to monitor progress, adjust treatment plans, and provide ongoing support
  • Use validated assessment tools to track symptom changes and treatment effectiveness over time

Clinical Highlights

  • Recognise and diagnose ARDS early through thorough clinical assessment, paying close attention to the rapid onset of dyspnoea, hypoxaemia, and bilateral pulmonary infiltrates
  • Rule out differential diagnoses such as cardiogenic pulmonary oedema, acute interstitial pneumonia, and diffuse alveolar haemorrhage
  • Initiate management with supportive care, including oxygen therapy, lung-protective mechanical ventilation strategies, and prone positioning to improve oxygenation
  • Tailor pharmacological therapy, utilising neuromuscular blockers like cisatracurium, corticosteroids such as methylprednisolone, and vasoactive agents like norepinephrine based on patient-specific factors
  • Regularly monitor and adjust treatment plans based on patient response, ensuring the management of potential complications such as barotrauma, nosocomial infections, and multiorgan failure
  • Implement preventive measures, including prophylactic anticoagulation for DVT and early mobilisation to prevent muscle atrophy and improve functional outcomes
  • Emphasise the importance of multidisciplinary care involving intensivists, pulmonologists, infectious disease specialists, and rehabilitation therapists for comprehensive management
  • Educate patients and families on the significance of treatment adherence, the potential side effects of medications, and the need for regular follow-ups to monitor progress and adjust treatments
  • Encourage lifestyle modifications, including maintaining a healthy diet, regular physical activity, and good sleep hygiene to support overall recovery
  • Provide psychological support to address the impact of ARDS on mental health, recognising the risk of PTSD, anxiety, and depression in survivors
  • Schedule regular follow-up appointments to monitor long-term outcomes, using validated assessment tools to track lung function and mental health
  • Prepare for long-term management, including pulmonary rehabilitation and potential long-term oxygen therapy, emphasising patient education and active involvement in care decisions
  • Keep abreast of updated guidelines and evidence-based practices for ARDS management, integrating new research findings into clinical practice to improve patient outcomes

Recommended reads

  1. Griffiths MJD, McAuley DF, Perkins GD, et al. Guidelines on the management of acute respiratory distress syndrome. BMJ Open Respir Res. 2019;6(1):e000420. Published 2019 May 24
  2. Diamond M, Peniston HL, Sanghavi DK, et al. Acute Respiratory Distress Syndrome. [Updated 2024 Jan 31]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-
  3. Bellani G, Laffey JG, Pham T, et al. Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. JAMA. 2016;315(8):788-800
  4. Fan E, Brodie D, Slutsky AS. Acute Respiratory Distress Syndrome: Advances in Diagnosis and Treatment. JAMA. 2018;319(7):698-710
  5. Papazian L, Calfee CS, Chiumello D, et al. Diagnostic workup for ARDS patients. Intensive Care Med. 2016;42(5):674-685
  6. Laffey JG, Madotto F, Bellani G, et al. Geo-economic variations in epidemiology, patterns of care, and outcomes in patients with acute respiratory distress syndrome: insights from the LUNG SAFE prospective cohort study. Lancet Respir Med. 2017;5(8):627-638
  7. Battaglini D, Fazzini B, Silva PL, et al. Challenges in ARDS Definition, Management, and Identification of Effective Personalized Therapies. J Clin Med. 2023;12(4):1381. Published 2023 Feb 9

Drugs mentioned

ICD-10 codes

NeoHealth® ID 38978 · updated 3/24/2026